Relay Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Relay Therapeutics Depreciation & Amortization Growth & History (RLAY)
Relay Therapeutics's depreciation and amortization was $3.6M for fiscal 2025.
View full Relay Therapeutics company overviewRelay Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.6M | −$1.9M | −34.90% |
| 2024 | 2024-12-31 | $5.5M | $195,000 | +3.70% |
| 2023 | 2023-12-31 | $5.3M | $1.1M | +27.58% |
| 2022 | 2022-12-31 | $4.1M | $205,000 | +5.22% |
| 2021 | 2021-12-31 | $3.9M | $376,000 | +10.59% |
| 2020 | 2020-12-31 | $3.5M | $704,000 | +24.75% |
| 2019 | 2019-12-31 | $2.8M | — | — |
Relay Therapeutics quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $360,000 | −$642,000 | −64.07% |
| Q1 2026 | 2026-03-31 | $504,000 | −$704,000 | −58.28% |
| Q4 2025 | 2025-12-31 | $599,000 | — | — |
| Q3 2025 | 2025-09-30 | $748,000 | −$619,000 | −45.28% |
| Q2 2025 | 2025-06-30 | $1.0M | −$366,000 | −26.75% |
| Q1 2025 | 2025-03-31 | $1.2M | −$187,000 | −13.41% |
| Q3 2024 | 2024-09-30 | $1.4M | $4,000 | +0.29% |
| Q2 2024 | 2024-06-30 | $1.4M | $34,000 | +2.55% |
| Q1 2024 | 2024-03-31 | $1.4M | $198,000 | +16.54% |
| Q3 2023 | 2023-09-30 | $1.4M | $330,000 | +31.95% |
| Q2 2023 | 2023-06-30 | $1.3M | $378,000 | +39.54% |
| Q1 2023 | 2023-03-31 | $1.2M | $222,000 | +22.77% |
| Q3 2022 | 2022-09-30 | $1.0M | $21,000 | +2.08% |
| Q2 2022 | 2022-06-30 | $956,000 | −$4,000 | −0.42% |
| Q1 2022 | 2022-03-31 | $975,000 | $56,000 | +6.09% |
| Q3 2021 | 2021-09-30 | $1.0M | $99,000 | +10.84% |
| Q2 2021 | 2021-06-30 | $960,000 | $95,000 | +10.98% |
| Q1 2021 | 2021-03-31 | $919,000 | $60,000 | +6.98% |
| Q3 2020 | 2020-09-30 | $913,000 | $279,000 | +44.01% |
| Q2 2020 | 2020-06-30 | $865,000 | — | — |
| Q1 2020 | 2020-03-31 | $859,000 | — | — |
| Q3 2019 | 2019-09-30 | $634,000 | — | — |
Relay Therapeutics depreciation and amortization trends
Over the last five fiscal years, Relay Therapeutics's depreciation and amortization increased from $3.5M to $3.6M, a change of $8,000. The latest reported quarter, Q2 2026, shows $360,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relay Therapeutics source filings ↗